JP2016519115A - ドラスタチン10およびアウリスタチンの誘導体 - Google Patents
ドラスタチン10およびアウリスタチンの誘導体 Download PDFInfo
- Publication number
- JP2016519115A JP2016519115A JP2016509483A JP2016509483A JP2016519115A JP 2016519115 A JP2016519115 A JP 2016519115A JP 2016509483 A JP2016509483 A JP 2016509483A JP 2016509483 A JP2016509483 A JP 2016509483A JP 2016519115 A JP2016519115 A JP 2016519115A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mmol
- methyl
- equiv
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC[C@](C)[C@@]([C@@](CC(OC(C)(C)C)=O)OC)N(C)C([C@](C(C)C)N*)=O Chemical compound CC[C@](C)[C@@]([C@@](CC(OC(C)(C)C)=O)OC)N(C)C([C@](C(C)C)N*)=O 0.000 description 2
- ARRDQERKJYYAOS-UHFFFAOYSA-N CC(C)C(C(O)=O)N(C)Cc1cccc(NC(OC(C)(C)C)=O)c1 Chemical compound CC(C)C(C(O)=O)N(C)Cc1cccc(NC(OC(C)(C)C)=O)c1 ARRDQERKJYYAOS-UHFFFAOYSA-N 0.000 description 1
- GKYLNZCTRDYZLD-FAYKJJBTSA-M CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1C(C(C)C(N[C@H](C)C(c1ccccc1)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)Cc1cc([N-]C(OC(C)(C)C)=O)ccc1)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1C(C(C)C(N[C@H](C)C(c1ccccc1)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)Cc1cc([N-]C(OC(C)(C)C)=O)ccc1)=O)=O GKYLNZCTRDYZLD-FAYKJJBTSA-M 0.000 description 1
- GSRYHPINZFCDJW-VFSYNPLYSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(O)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCCN)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(O)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCCN)=O)=O GSRYHPINZFCDJW-VFSYNPLYSA-N 0.000 description 1
- VQSMLSMVLAFVGC-FBIGSRELSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@H](C)C(c1ccccc1)O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)N)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@H](C)C(c1ccccc1)O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)N)=O VQSMLSMVLAFVGC-FBIGSRELSA-N 0.000 description 1
- XJKHMAUKQMUOGF-IOASZLSFSA-N CC[C@H](CC1)[C@@]1([C@@H](CC(OC(C)(C)C)=O)OC)N(C)C Chemical compound CC[C@H](CC1)[C@@]1([C@@H](CC(OC(C)(C)C)=O)OC)N(C)C XJKHMAUKQMUOGF-IOASZLSFSA-N 0.000 description 1
- DFLGWAFOSVGKKK-UHFFFAOYSA-N CN(C(Cc1ccccc1)=O)OC Chemical compound CN(C(Cc1ccccc1)=O)OC DFLGWAFOSVGKKK-UHFFFAOYSA-N 0.000 description 1
- HCGLADHPDDVLRL-UHFFFAOYSA-N C[BrH]c1ncc[s]1 Chemical compound C[BrH]c1ncc[s]1 HCGLADHPDDVLRL-UHFFFAOYSA-N 0.000 description 1
- XJDVGABQIFOWFC-SCQOQHIRSA-N C[C@H]([C@H]([C@H](CCC1)N1C(OC(C)(C)C)=O)OC)C(N[C@H](C)[C@H](c1ccccc1)O)=O Chemical compound C[C@H]([C@H]([C@H](CCC1)N1C(OC(C)(C)C)=O)OC)C(N[C@H](C)[C@H](c1ccccc1)O)=O XJDVGABQIFOWFC-SCQOQHIRSA-N 0.000 description 1
- DLNKOYKMWOXYQA-VXNVDRBHSA-N C[C@H]([C@H](c1ccccc1)O)N Chemical compound C[C@H]([C@H](c1ccccc1)O)N DLNKOYKMWOXYQA-VXNVDRBHSA-N 0.000 description 1
- AVQUQUPRIYRNFZ-UHFFFAOYSA-N O=C(Cc1ccccc1)c1ncc[s]1 Chemical compound O=C(Cc1ccccc1)c1ncc[s]1 AVQUQUPRIYRNFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
R1は、HまたはOHであり、
R2は、基:(C1−C6)アルキル(例えば、メチル)、COOH、COO−((C1−C6)アルキル)(例えば、COOMe)またはチアゾリル(例えば、チアゾール−2−イル)であり、
R3は、Hまたは(C1−C6)アルキル基(例えば、メチル)、特に、(C1−C6)アルキル基であり、かつ、
R4は、OHおよびNR9R10基から選択される1以上の基(特に、1つ、好ましくは、アリール部分上)で置換されたアリール−(C1−C8)アルキル基であり、ここで、R9およびR10はそれぞれ互いに独立にHまたは(C1−C6)アルキル基(例えば、メチル)を表す]
またはその薬学的に許容可能な塩、水和物もしくは溶媒和物。
(1)塩酸、臭化水素酸、リン酸、硫酸および類似の酸などの薬学的に許容可能な無機酸を伴って形成される;または酢酸、トリフルオロ酢酸、プロピオン酸、コハク酸、フマル酸、リンゴ酸、酒石酸、クエン酸、アスコルビン酸、マレイン酸、グルタミン酸、安息香酸、サリチル酸、トルエンスルホン酸、メタンスルホン酸、ステアリン酸、乳酸および類似の酸などの薬学的に許容可能な有機酸を伴って形成される薬学的に許容可能な酸の付加塩;および
(2)親化合物中に存在する酸プロトンが、金属イオン、例えば、アルカリ金属イオン、アルカリ土類金属イオンもしくはアルミニウムイオンで置換されているか、またはリシン、アルギニンおよび類似物などの薬学的に許容可能な有機塩基とともに;または水酸化ナトリウム、水酸化カリウム、水酸化カルシウムおよび類似物などの薬学的に許容可能な無機塩基とともに配位している、薬学的に許容可能な塩基の付加塩
を含んでなる。
R1=OHおよびR2=Me(メチル)、または
R1=HおよびR2=COOH、COOMeまたはチアゾール−2−イル
の式(I)の化合物である。
と下式(VII)の化合物:
の間の縮合反応を含んでなる、式(I)の化合物を製造するための第1の方法である。
と下式(X)の化合物:
R4a−Y (X)
(式中、R4aは、場合により保護形態の、従前に定義されているものなどのR4基であり、Yは、Cl、Br、I、OSO2CH3、OSO2CF3またはO−トシルなどの脱離基である)
の間の置換反応を含んでなる、式(I)の化合物を製造するための第2の方法である。
と下式(XI)の化合物:
R4b−CHO (XI)
(式中、R4bは上記で定義されるものなどである)
の間の還元的アミノ化反応を含んでなる方法である。
ここで、RGP1は、FまたはClなどの1または数個のハロゲン原子で置換されていてもよい(C1−C6)アルキル;アリルなどの(C2−C6)アルケニル;OMe(メトキシ)およびNO2(ニトロ)から選択される1または数個の基で置換されていてもよい、フェニルなどのアリール;アリール部分が1または数個のメトキシ基で置換されていてもよい、ベンジルなどのアリール−(C1−C6)アルキル;または9−フルオレニルメチル基を表す。
I−本発明の化合物の合成
下記の略語を下記の実施例で使用する。
aq. 水性
ee 鏡像体過剰率
equiv 当量
ESI エレクトロスプレーイオン化
LC/MS 質量分析と連結した液体クロマトグラフィー
HPLC 高速液体クロマトグラフィー
NMR 核磁気共鳴
sat. 飽和
UV 紫外線
(S)−2−((S)−2−((3−アミノプロピル)(メチル)アミノ)−3−メチルブタンアミド)−N−((3R,4S,5S)−3−メトキシ−1−((S)−2−((1R,2R)−1−メトキシ−2−メチル−3−オキソ−3−(((S)−2−フェニル−1−(チアゾール−2−イル)エチル)アミノ)プロピル)ピロリジン−1−イル)−5−メチル−1−オキソヘプタン−4−イル)−N,3−ジメチルブタンアミド,ビストリフルオロ酢酸
(S)−2−((S)−2−(((2−アミノピリジン−4−イル)メチル)(メチル)アミノ)−3−メチルブタンアミド)−N−((3R,4S,5S)−1−((S)−2−((1R,2R)−3−(((1S,2R)−1−ヒドロキシ−1−フェニルプロパン−2−イル)アミノ)−1−メトキシ−2−メチル−3−オキソプロピル)ピロリジン−1−イル)−3−メトキシ−5−メチル−1−オキソヘプタン−4−イル)−N,3−ジメチルブタンアミド,トリフルオロ酢酸
((S)−2−((2R,3R)−3−((S)−1−((3R,4S,5S)−4−((S)−N,3−ジメチル−2−((S)−3−メチル−2−(メチル(ピリジン−4−イルメチル)アミノ)ブタンアミド)ブタンアミド)−3−メトキシ−5−メチルヘプタノイル)ピロリジン−2−イル)−3−メトキシ−2−メチルプロパンアミド)−3−フェニルプロパン酸メチル,トリフルオロ酢酸
(S)−2−((2R,3R)−3−((S)−1−((3R,4S,5S)−4−((S)−N,3−ジメチル−2−((S)−3−メチル−2−(メチル(ピリジン−4−イルメチル)アミノ)ブタンアミド)ブタンアミド)−3−メトキシ−5−メチルヘプタノイル)ピロリジン−2−イル)−3−メトキシ−2−メチルプロパンアミド)−3−フェニルプロパン酸,トリフルオロ酢酸
(S)−2−((2R,3R)−3−((S)−1−((3R,4S,5S)−4−((S)−2−((S)−2−((3−アミノプロピル)(メチル)アミノ)−3−メチルブタンアミド)−N,3−ジメチルブタンアミド)−3−メトキシ−5−メチルヘプタノイル)ピロリジン−2−イル)−3−メトキシ−2−メチルプロパンアミド)−3−フェニルプロパン酸メチル、ビストリフルオロ酢酸
(S)−2−((2R,3R)−3−((S)−1−((3R,4S,5S)−4−((S)−2−((S)−2−((3−アミノプロピル)(メチル)アミノ)−3−メチルブタンアミド)−N,3−ジメチルブタンアミド)−3−メトキシ−5−メチルヘプタノイル)ピロリジン−2−イル)−3−メトキシ−2−メチルプロパンアミド)−3−フェニルプロパン酸、ビストリフルオロ酢酸
(S)−N−((3R,4S,5S)−3−メトキシ−1−((S)−2−((1R,2R)−1−メトキシ−2−メチル−3−オキソ−3−(((S)−2−フェニル−1−(チアゾール−2−イル)エチル)アミノ)プロピル)ピロリジン−1−イル)−5−メチル−1−オキソヘプタン−4−イル)−N,3−ジメチル−2−((S)−3−メチル−2−(メチル(4−(メチルアミノ)フェネチル)アミノ)ブタンアミド)ブタンアミド,トリフルオロ酢酸
化合物11Aは、周囲温度、THF中での2−(4−アミノフェニル)エタノールとBOC2Oの反応の後に75%の収率で得られた。
(S)−2−((2R,3R)−3−((S)−1−((3R,4S,5S)−4−((S)−N,3−ジメチル−2−((S)−3−メチル−2−(メチル(4−(メチルアミノ)フェネチル)アミノ)ブタンアミド)ブタンアミド)−3−メトキシ−5−メチルヘプタノイル)ピロリジン−2−イル)−3−メトキシ−2−メチルプロパンアミド)−3−フェニルプロパン酸メチル,トリフルオロ酢酸
(S)−2−((2R,3R)−3−((S)−1−((3R,4S,5S)−4−((S)−N,3−ジメチル−2−((S)−3−メチル−2−(メチル(4−(メチルアミノ)フェネチル)アミノ)ブタンアミド)ブタンアミド)−3−メトキシ−5−メチルヘプタノイル)ピロリジン−2−イル)−3−メトキシ−2−メチルプロパンアミド)−3−フェニルプロパン酸,トリフルオロ酢酸
(S)−2−((S)−2−((3−アミノベンジル)(メチル)アミノ)−3−メチルブタンアミド)−N−((3R,4S,5S)−3−メトキシ−1−((S)−2−((1R,2R)−1−メトキシ−2−メチル−3−オキソ−3−(((S)−2−フェニル−1−(チアゾール−2−イル)エチル)アミノ)プロピル)ピロリジン−1−イル)−5−メチル−1−オキソヘプタン−4−イル)−N,3−ジメチルブタンアミド,トリフルオロ酢酸
(S)−2−((2R,3R)−3−((S)−1−((3R,4S,5S)−4−((S)−2−((S)−2−((3−アミノベンジル)(メチル)アミノ)−3−メチルブタンアミド)−N,3−ジメチルブタンアミド)−3−メトキシ−5−メチルヘプタノイル)ピロリジン−2−イル)−3−メトキシ−2−メチルプロパンアミド)−3−フェニルプロパン酸メチル,トリフルオロ酢酸
化合物19 LC/MS/UV ESI: (C48H72N6O7S, 精密質量876.52) m/z 877 (MH+), 439 [100 %, (M.2H+)/2]; UV: RT = 1.76分 (93.2 %, 220 nm)。
化合物23 LC/MS/UV (ESI) (C46H73N5O8, 精密質量823.55) m/z 824 (MH+), 846 (MNa+), 413 (100 %, (M.2H+)/2); UV: 4.76分 (98.5 %, 215 nm)。1H NMR (400MHz, CDCl3, ppm): δ (回転異性体の存在) 7.5-7.2 (m, 5H); 7.9-7.75 (m, 2H); 5.5-5.3 (m, 1H); 4.9-4.6 (m, 2H); 4.55-4.15 (m, 4H); 4.0−0.8 (m, 55H)。
(S)−2−((2R,3R)−3−((S)−1−((3R,4S,5S)−4−((S)−2−((S)−2−((4−ヒドロキシフェネチル)(メチル)アミノ)−3−メチルブタンアミド)−N,3−ジメチルブタンアミド)−3−メトキシ−5−メチルヘプタノイル)ピロリジン−2−イル)−3−メトキシ−2−メチルプロパンアミド)−3−フェニルプロパン酸メチル,トリフルオロ酢酸
(S)−2−((S)−2−((3−アミノベンジル)(メチル)アミノ)−3−メチルブタンアミド)−N−((3R,4S,5S)−1−((S)−2−((1R,2R)−3−(((1S,2R)−1−ヒドロキシ−1−フェニルプロパン−2−イル)アミノ)−1−メトキシ−2−メチル−3−オキソプロピル)ピロリジン−1−イル)−3−メトキシ−5−メチル−1−オキソヘプタン−4−イル)−N,3−ジメチルブタンアミド,トリフルオロ酢酸
(S)−2−((2R,3R)−3−((S)−1−((3R,4S,5S)−4−((S)−2−((S)−2−((3−アミノベンジル)(メチル)アミノ)−3−メチルブタンアミド)−N,3−ジメチルブタンアミド)−3−メトキシ−5−メチルヘプタノイル)ピロリジン−2−イル)−3−メトキシ−2−メチルプロパンアミド)−3−フェニルプロパン酸、トリフルオロ酢酸
(S)−2−((S)−2−((4−ヒドロキシフェネチル)(メチル)アミノ)−3−メチルブタンアミド)−N−((3R,4S,5S)−3−メトキシ−1−((S)−2−((1R,2R)−1−メトキシ−2−メチル−3−オキソ−3−(((S)−2−フェニル−1−(チアゾール−2−イル)エチル)アミノ)プロピル)ピロリジン−1−イル)−5−メチル−1−オキソヘプタン−4−イル)−N,3−ジメチルブタンアミド,トリフルオロ酢酸
(S)−2−((2R,3R)−3−((S)−1−((3R,4S,5S)−4−((S)−2−((S)−2−((4−ヒドロキシフェネチル)(メチル)アミノ)−3−メチルブタンアミド)−N,3−ジメチルブタンアミド)−3−メトキシ−5−メチルヘプタノイル)ピロリジン−2−イル)−3−メトキシ−2−メチルプロパンアミド)−3−フェニルプロパン酸,トリフルオロ酢酸
(S)−2−((2R,3R)−3−((S)−1−((3R,4S,5S)−4−((S)−2−((S)−2−((4−ヒドロキシベンジル)(メチル)アミノ)−3−メチルブタンアミド)−N,3−ジメチルブタンアミド)−3−メトキシ−5−メチルヘプタノイル)ピロリジン−2−イル)−3−メトキシ−2−メチルプロパンアミド)−3−フェニルプロパン酸メチル,トリフルオロ酢酸
(S)−2−((S)−2−((4−アミノフェネチル)(メチル)アミノ)−3−メチルブタンアミド)−N−((3R,4S,5S)−3−メトキシ−1−((S)−2−((1R,2R)−1−メトキシ−2−メチル−3−オキソ−3−(((S)−2−フェニル−1−(チアゾール−2−イル)エチル)アミノ)プロピル)ピロリジン−1−イル)−5−メチル−1−オキソヘプタン−4−イル)−N,3−ジメチルブタンアミド
メチル((2R,3R)−3−((S)−1−((3R,4S,5S)−4−((S)−2−((S)−2−((4−アミノフェネチル)(メチル)アミノ)−3−メチルブタンアミド)−N,3−ジメチルブタンアミド)−3−メトキシ−5−メチルヘプタノイル)ピロリジン−2−イル)−3−メトキシ−2−メチルプロパノイル)−L−フェニルアラニネート
2,2,2−トリフルオロ酢酸((2R,3R)−3−((S)−1−((3R,4S,5S)−4−((S)−2−((S)−2−((4−アミノフェネチル)(メチル)アミノ)−3−メチルブタンアミド)−N,3−ジメチルブタンアミド)−3−メトキシ−5−メチルヘプタノイル)ピロリジン−2−イル)−3−メトキシ−2−メチルプロパノイル)−L−フェニルアラニン
(S)−2−((S)−2−((4−アミノフェネチル)(メチル)アミノ)−3−メチルブタンアミド)−N−((3R,4S,5S)−1−((S)−2−((1R,2R)−3−(((1S,2R)−1−ヒドロキシ−1−フェニルプロパン−2−イル)アミノ)−1−メトキシ−2−メチル−3−オキソプロピル)ピロリジン−1−イル)−3−メトキシ−5−メチル−1−オキソヘプタン−4−イル)−N,3−ジメチルブタンアミド
方法:
細胞培養
A549(非小細胞肺癌−ATCC CCL−185)細胞およびMDA−MB−231(乳腺癌−ATCC HTB−26)細胞をそれぞれ、5%ウシ胎児血清(FCS)を含むイーグル最小必須培地(MEM)および10%FCSを含むダルベッコの改変イーグル培地(DMEM)で培養した。MCF7(乳管癌−ATCC HTB−22)細胞およびSN−12C(腎臓癌−ATCC)細胞は、10%FCSを含有するRPMI1640培地(MCF7細胞の場合にはフェノールレッド不含)で維持した。総ての培地にファンギゾン(1.25μg/mL)およびペニシリン−ストレプトマイシン(100U/100μg/mL)を添加した。細胞を37℃、5%CO2および95%大気湿度のインキュベーターにて、標準条件下で培養した。
本発明による化合物を、4種の細胞株の包括的パネルにおけるATPlite増殖アッセイ(Perkin Elmer、ヴィルボン・シュル・イヴェット、フランス)を用い、それらの抗増殖活性に関して調べた。0日目に、細胞を96ウェルプレートに、細胞が72時間の薬物処理期間に対数細胞増殖期に留まるような密度(A549の場合には103細胞/ウェル、MCF7、MDA−MB−231およびSN12Cの場合には2.103細胞/ウェル)で播種した。24時間のインキュベーション期間の後、総ての細胞を供試化合物の希釈系(1%DMSO中、10倍溶液11μL−6ウェル/条件)で処理した。化合物のチップへの付着を避けるため、2つの連続する希釈液の間ではチップを交換した。次に、細胞を37℃、5%CO2インキュベーターに入れた。4日目に、細胞生存率を生存細胞によって放出されるATPを測定する(dosing)ことによって評価した。生存細胞の数を溶媒処理細胞の数と比較して分析した。EC50値は、GraphPadソフトウエア(GraphPad Software Inc.、CA、USA)が提供しているアルゴリズムを用いて実行する曲線フィッティング解析(S字用量応答、変数としてのヒル係数を用いた非線形回帰モデル)を用いて決定した。
種々の化合物:
本発明による種々の化合物を、上記の方法に従ってMDA−MB−231細胞株に対するそれらの抗増殖活性を決定するために試験した。測定された活性はEC50<0.1μMの値を示した。
実施例12:EC50=5.80×10−10M;実施例13:EC50=7.95×10−8M;実施例15:EC50=1.70×10−10M;実施例27:EC50=1.20×10−10M。
化合物15を、上記の方法に従い、種々の細胞株(A549、MDA−MB−231、MCF−7、SN12C)で試験した。測定された活性はEC50<0.1μMの値を示した。
フェニル環での置換(アミノ/ヒドロキシル対カルボキシル)を下記の比較例で検討したところ、アミノまたはヒドロキシル置換基を含んでなる本発明による薬物の抗増殖活性の改善が示された。
Claims (16)
- R1=OH、かつ、R2が(C1−C6)アルキル基を表すか、または
R1=H、かつ、R2がCOOH、COO−(C1−C6)アルキルまたはチアゾール基を表す、請求項1に記載の化合物。 - R1がHを表し、R2がCOOHまたはCOOMeを表す、請求項1または2に記載の化合物。
- R3がHまたはメチル基を表す、請求項1〜3のいずれか一項に記載の化合物。
- R4が、アリール部分において、OHおよびNR9R10基から選択される、特にNR9R10である1つの基で置換されたアリール−(C1−C4)アルキル基を表す、請求項1〜4のいずれか一項に記載の化合物。
- R4が、フェニル部分において、OHおよびNR9R10基から選択される、特にNR9R10である1つの基で置換されたフェニル−(C1−C2)アルキル基を表す、請求項1〜4のいずれか一項に記載の化合物。
- 医薬品として使用するための請求項1〜9のいずれか一項に記載の化合物。
- 癌または良性増殖性障害の治療を意図した医薬品として使用するための、請求項1〜9のいずれか一項に記載の化合物。
- 請求項1〜9のいずれか一項に記載の式(I)の化合物と少なくとも1つの薬学的に許容可能な賦形剤とを含んでなる医薬組成物。
- 有利には、特に、ナベルビン、ビンフルニン、タキソール、タキソテール(taxoter)、5−フルオロウラシル、メトトレキサート、ドキソルビシン(doxorabicin)、カンプトテシン、ゲムシタビン(gemcitabin)、エトポシド、シスプラチンまたはカルムスチン(carmustine)などの細胞傷害性抗癌薬;およびタモキシフェンまたはメドロキシプロゲステロンなどのホルモン抗癌薬を含んでなる抗癌剤から選択される別の有効成分をさらに含んでなる、請求項12に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1353793 | 2013-04-25 | ||
FR1353793A FR3005051A1 (fr) | 2013-04-25 | 2013-04-25 | Derives de la dolastatine 10 et d'auristatines |
PCT/EP2014/058427 WO2014174064A1 (en) | 2013-04-25 | 2014-04-25 | Derivatives of dolastatin 10 and auristatins |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016519115A true JP2016519115A (ja) | 2016-06-30 |
JP6017728B2 JP6017728B2 (ja) | 2016-11-02 |
Family
ID=48782433
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016509483A Active JP6017728B2 (ja) | 2013-04-25 | 2014-04-25 | ドラスタチン10およびアウリスタチンの誘導体 |
JP2016509480A Active JP6606489B2 (ja) | 2013-04-25 | 2014-04-25 | ドラスタチン10およびアウリスタチンの誘導体 |
JP2016509482A Pending JP2016519114A (ja) | 2013-04-25 | 2014-04-25 | ドラスタチン10およびアウリスタチンの誘導体 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016509480A Active JP6606489B2 (ja) | 2013-04-25 | 2014-04-25 | ドラスタチン10およびアウリスタチンの誘導体 |
JP2016509482A Pending JP2016519114A (ja) | 2013-04-25 | 2014-04-25 | ドラスタチン10およびアウリスタチンの誘導体 |
Country Status (32)
Country | Link |
---|---|
US (7) | US20160068567A1 (ja) |
EP (4) | EP2989088B1 (ja) |
JP (3) | JP6017728B2 (ja) |
KR (4) | KR101640361B1 (ja) |
CN (3) | CN105377834B (ja) |
AU (3) | AU2014259429A1 (ja) |
BR (3) | BR112015026478A2 (ja) |
CA (4) | CA2910178A1 (ja) |
CY (2) | CY1119677T1 (ja) |
DK (3) | DK2989088T3 (ja) |
ES (3) | ES2693368T3 (ja) |
FR (1) | FR3005051A1 (ja) |
HK (2) | HK1215580A1 (ja) |
HR (2) | HRP20171977T1 (ja) |
HU (3) | HUE058167T2 (ja) |
IL (1) | IL242184A (ja) |
LT (2) | LT2989088T (ja) |
MA (1) | MA38583B1 (ja) |
MX (3) | MX345126B (ja) |
MY (1) | MY177702A (ja) |
NO (1) | NO2989088T3 (ja) |
NZ (1) | NZ714203A (ja) |
PL (3) | PL3388427T3 (ja) |
PT (2) | PT2989086T (ja) |
RS (2) | RS56717B1 (ja) |
RU (3) | RU2015146957A (ja) |
SA (1) | SA515370043B1 (ja) |
SI (2) | SI2989088T1 (ja) |
TN (2) | TN2015000445A1 (ja) |
UA (1) | UA115806C2 (ja) |
WO (3) | WO2014174062A1 (ja) |
ZA (1) | ZA201508545B (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
WO2015162291A1 (en) | 2014-04-25 | 2015-10-29 | Pierre Fabre Medicament | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer |
RU2685259C2 (ru) * | 2014-04-25 | 2019-04-17 | Пьер Фабр Медикамент | Конъюгат антитела и лекарственного средства и его применение для лечения рака |
ES2785551T3 (es) | 2014-06-30 | 2020-10-07 | Glykos Finland Oy | Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos |
BR112018016983A2 (pt) * | 2016-02-26 | 2018-12-26 | Jiangsu Hengrui Medicine Co., Ltd. | nova toxina e método de preparação de intermediário da mesma |
FI3438118T3 (fi) * | 2016-03-29 | 2023-06-15 | Toray Industries | Peptidijohdannainen ja sen käyttö |
CN105968038A (zh) * | 2016-05-09 | 2016-09-28 | 湖北华世通生物医药科技有限公司 | 二肽类化合物的盐酸盐及其制备方法 |
CN106432318A (zh) * | 2016-08-18 | 2017-02-22 | 重庆大学 | 一种芳炔前体的设计,合成,及在合成多取代芳烃的应用 |
CN107325033A (zh) * | 2017-06-23 | 2017-11-07 | 华东师范大学 | 一种高立体选择性合成海兔毒素Dap片段的方法 |
WO2019108974A1 (en) * | 2017-11-30 | 2019-06-06 | Centurion Biopharma Corporation | Albumin-binding prodrugs of auristatin e derivatives |
MX2021003295A (es) | 2018-09-27 | 2021-07-16 | Pf Medicament | Enlazadores basados en sulfomaleimida y sus correspondientes conjugados. |
CN110724337B (zh) * | 2019-10-16 | 2022-04-05 | 江苏德威新材料股份有限公司 | 一种硅烷交联型阻燃半导电聚烯烃护套材料及其制备方法和应用 |
KR20240051956A (ko) | 2021-09-03 | 2024-04-22 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995009864A1 (fr) * | 1993-10-01 | 1995-04-13 | Teikoku Hormone Mfg. Co., Ltd. | Nouveau derive peptidique |
WO2011154359A1 (de) * | 2010-06-10 | 2011-12-15 | Bayer Pharma Aktiengesellschaft | Neue auristatin-derivate und ihre verwendung |
WO2012041805A1 (de) * | 2010-09-29 | 2012-04-05 | Bayer Pharma Aktiengesellschaft | N-carboxyalkyl-auristatine und ihre verwendung |
WO2012059882A2 (en) * | 2010-11-05 | 2012-05-10 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
WO2012123423A1 (de) * | 2011-03-16 | 2012-09-20 | Bayer Pharma Aktiengesellschaft | N-carboxyalkyl-auristatine und ihre verwendung |
WO2012166559A1 (en) * | 2011-05-27 | 2012-12-06 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6884869B2 (en) * | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
WO2007008603A1 (en) * | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
RU2556129C2 (ru) * | 2008-04-11 | 2015-07-10 | Сиэтл Дженетикс, Инк. | Диагностика и лечение злокачественных опухолей поджелудочной железы, яичников и других злокачественных опухолей |
CN102448486A (zh) * | 2009-03-06 | 2012-05-09 | 艾更斯司股份有限公司 | 结合于24p4c12蛋白的抗体药物偶联物(adc) |
CN103826661B (zh) * | 2011-04-21 | 2019-03-05 | 西雅图基因公司 | 新的结合剂-药物缀合物(adc)及其用途 |
KR102030856B1 (ko) * | 2011-05-27 | 2019-10-10 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
NZ703298A (en) * | 2012-06-07 | 2016-04-29 | Ambrx Inc | Prostate-specific membrane antigen antibody drug conjugates |
EP3488870B1 (en) * | 2012-06-19 | 2024-03-20 | Ambrx, Inc. | Anti-cd70 antibody drug conjugates |
EP2934596A1 (en) * | 2012-12-21 | 2015-10-28 | Glykos Finland Oy | Linker-payload molecule conjugates |
FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
RU2685259C2 (ru) * | 2014-04-25 | 2019-04-17 | Пьер Фабр Медикамент | Конъюгат антитела и лекарственного средства и его применение для лечения рака |
-
2013
- 2013-04-25 FR FR1353793A patent/FR3005051A1/fr not_active Withdrawn
-
2014
- 2014-04-25 RS RS20171344A patent/RS56717B1/sr unknown
- 2014-04-25 CN CN201480030093.0A patent/CN105377834B/zh active Active
- 2014-04-25 HU HUE18172389A patent/HUE058167T2/hu unknown
- 2014-04-25 WO PCT/EP2014/058425 patent/WO2014174062A1/en active Application Filing
- 2014-04-25 MX MX2015014941A patent/MX345126B/es active IP Right Grant
- 2014-04-25 DK DK14720946.4T patent/DK2989088T3/en active
- 2014-04-25 PL PL18172389T patent/PL3388427T3/pl unknown
- 2014-04-25 DK DK14719328.8T patent/DK2989086T3/en active
- 2014-04-25 HU HUE14720946A patent/HUE035180T2/hu unknown
- 2014-04-25 RU RU2015146957A patent/RU2015146957A/ru unknown
- 2014-04-25 CA CA2910178A patent/CA2910178A1/en not_active Abandoned
- 2014-04-25 US US14/784,163 patent/US20160068567A1/en not_active Abandoned
- 2014-04-25 MY MYPI2015703517A patent/MY177702A/en unknown
- 2014-04-25 WO PCT/EP2014/058427 patent/WO2014174064A1/en active Application Filing
- 2014-04-25 EP EP14720946.4A patent/EP2989088B1/en active Active
- 2014-04-25 CN CN201480023286.3A patent/CN105143199A/zh active Pending
- 2014-04-25 US US14/786,921 patent/US20160083420A1/en not_active Abandoned
- 2014-04-25 PL PL14719328T patent/PL2989086T3/pl unknown
- 2014-04-25 CA CA2910176A patent/CA2910176C/en active Active
- 2014-04-25 NO NO14720946A patent/NO2989088T3/no unknown
- 2014-04-25 PT PT14719328T patent/PT2989086T/pt unknown
- 2014-04-25 TN TN2015000445A patent/TN2015000445A1/en unknown
- 2014-04-25 LT LTEP14720946.4T patent/LT2989088T/lt unknown
- 2014-04-25 JP JP2016509483A patent/JP6017728B2/ja active Active
- 2014-04-25 EP EP18172389.1A patent/EP3388427B1/en active Active
- 2014-04-25 MX MX2015014746A patent/MX2015014746A/es active IP Right Grant
- 2014-04-25 NZ NZ714203A patent/NZ714203A/en not_active IP Right Cessation
- 2014-04-25 AU AU2014259429A patent/AU2014259429A1/en not_active Abandoned
- 2014-04-25 RU RU2015149527A patent/RU2662951C2/ru active
- 2014-04-25 BR BR112015026478A patent/BR112015026478A2/pt not_active Application Discontinuation
- 2014-04-25 JP JP2016509480A patent/JP6606489B2/ja active Active
- 2014-04-25 UA UAA201511563A patent/UA115806C2/uk unknown
- 2014-04-25 RS RS20181410A patent/RS58161B1/sr unknown
- 2014-04-25 SI SI201430523T patent/SI2989088T1/en unknown
- 2014-04-25 BR BR112015026410-7A patent/BR112015026410B1/pt not_active IP Right Cessation
- 2014-04-25 MA MA38583A patent/MA38583B1/fr unknown
- 2014-04-25 KR KR1020157033194A patent/KR101640361B1/ko active IP Right Grant
- 2014-04-25 RU RU2015147447A patent/RU2015147447A/ru unknown
- 2014-04-25 PT PT147209464T patent/PT2989088T/pt unknown
- 2014-04-25 PL PL14720946T patent/PL2989088T3/pl unknown
- 2014-04-25 HU HUE14719328A patent/HUE040431T2/hu unknown
- 2014-04-25 DK DK18172389.1T patent/DK3388427T3/da active
- 2014-04-25 CN CN201480032708.3A patent/CN105408318A/zh active Pending
- 2014-04-25 ES ES14719328.8T patent/ES2693368T3/es active Active
- 2014-04-25 LT LTEP14719328.8T patent/LT2989086T/lt unknown
- 2014-04-25 KR KR1020157033192A patent/KR102368136B1/ko active IP Right Grant
- 2014-04-25 JP JP2016509482A patent/JP2016519114A/ja active Pending
- 2014-04-25 WO PCT/EP2014/058422 patent/WO2014174060A1/en active Application Filing
- 2014-04-25 AU AU2014259431A patent/AU2014259431B2/en not_active Ceased
- 2014-04-25 ES ES14720946.4T patent/ES2654364T3/es active Active
- 2014-04-25 AU AU2014259427A patent/AU2014259427B2/en not_active Ceased
- 2014-04-25 US US14/783,003 patent/US20160068566A1/en not_active Abandoned
- 2014-04-25 EP EP14719328.8A patent/EP2989086B1/en active Active
- 2014-04-25 KR KR1020157033193A patent/KR20160003735A/ko not_active Application Discontinuation
- 2014-04-25 CA CA3130994A patent/CA3130994A1/en active Pending
- 2014-04-25 SI SI201430953T patent/SI2989086T1/sl unknown
- 2014-04-25 BR BR112015026565A patent/BR112015026565A2/pt not_active IP Right Cessation
- 2014-04-25 KR KR1020217012000A patent/KR102389167B1/ko active IP Right Grant
- 2014-04-25 ES ES18172389T patent/ES2908224T3/es active Active
- 2014-04-25 MX MX2015014831A patent/MX2015014831A/es unknown
- 2014-04-25 EP EP14719330.4A patent/EP2989087A1/en not_active Withdrawn
- 2014-04-25 CA CA2909126A patent/CA2909126A1/en not_active Abandoned
-
2015
- 2015-09-28 TN TN2015000439A patent/TN2015000439A1/en unknown
- 2015-10-20 IL IL242184A patent/IL242184A/en active IP Right Grant
- 2015-10-22 SA SA515370043A patent/SA515370043B1/ar unknown
- 2015-11-19 ZA ZA2015/08545A patent/ZA201508545B/en unknown
-
2016
- 2016-03-29 HK HK16103554.4A patent/HK1215580A1/zh unknown
- 2016-04-05 HK HK16103846.2A patent/HK1215867A1/zh unknown
-
2017
- 2017-09-19 US US15/708,685 patent/US20180222858A1/en not_active Abandoned
- 2017-12-15 CY CY20171101313T patent/CY1119677T1/el unknown
- 2017-12-20 HR HRP20171977TT patent/HRP20171977T1/hr unknown
-
2018
- 2018-11-14 HR HRP20181890TT patent/HRP20181890T1/hr unknown
- 2018-11-15 CY CY181101213T patent/CY1120863T1/el unknown
-
2019
- 2019-05-30 US US16/426,532 patent/US20200010414A1/en not_active Abandoned
-
2020
- 2020-10-27 US US17/081,162 patent/US20210107868A1/en not_active Abandoned
-
2022
- 2022-08-11 US US17/819,089 patent/US20230002316A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995009864A1 (fr) * | 1993-10-01 | 1995-04-13 | Teikoku Hormone Mfg. Co., Ltd. | Nouveau derive peptidique |
WO2011154359A1 (de) * | 2010-06-10 | 2011-12-15 | Bayer Pharma Aktiengesellschaft | Neue auristatin-derivate und ihre verwendung |
WO2012041805A1 (de) * | 2010-09-29 | 2012-04-05 | Bayer Pharma Aktiengesellschaft | N-carboxyalkyl-auristatine und ihre verwendung |
WO2012059882A2 (en) * | 2010-11-05 | 2012-05-10 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
WO2012123423A1 (de) * | 2011-03-16 | 2012-09-20 | Bayer Pharma Aktiengesellschaft | N-carboxyalkyl-auristatine und ihre verwendung |
WO2012166559A1 (en) * | 2011-05-27 | 2012-12-06 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6017728B2 (ja) | ドラスタチン10およびアウリスタチンの誘導体 | |
OA17576A (en) | Derivatives of dolastatin 10 and auristatins. | |
OA17575A (en) | Derivatives of dolastatin 10 and auristatins. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20160401 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20160425 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160506 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160804 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160902 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160928 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6017728 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |